NO20005043D0 - Formulering av hurtigoppløsende efavirenz-kapsler eller - tabletter som benytter super-desintegreringsmidler - Google Patents

Formulering av hurtigoppløsende efavirenz-kapsler eller - tabletter som benytter super-desintegreringsmidler

Info

Publication number
NO20005043D0
NO20005043D0 NO20005043A NO20005043A NO20005043D0 NO 20005043 D0 NO20005043 D0 NO 20005043D0 NO 20005043 A NO20005043 A NO 20005043A NO 20005043 A NO20005043 A NO 20005043A NO 20005043 D0 NO20005043 D0 NO 20005043D0
Authority
NO
Norway
Prior art keywords
disintegrants
tablets
super
formulation
fast
Prior art date
Application number
NO20005043A
Other languages
English (en)
Other versions
NO20005043L (no
NO325824B1 (no
Inventor
William T Makooi-Morehead
John D Buehler
Brian R Landmann
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22160544&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20005043(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Publication of NO20005043L publication Critical patent/NO20005043L/no
Publication of NO20005043D0 publication Critical patent/NO20005043D0/no
Publication of NO325824B1 publication Critical patent/NO325824B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20005043A 1998-04-07 2000-10-06 Efavirenz-kapsler eller -tabletter som omfatter et desintegreringsmiddel og en fremgangsmate for fremstilling av disse. NO325824B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8092598P 1998-04-07 1998-04-07
PCT/US1999/007228 WO1999051239A1 (en) 1998-04-07 1999-04-01 Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants

Publications (3)

Publication Number Publication Date
NO20005043L NO20005043L (no) 2000-10-06
NO20005043D0 true NO20005043D0 (no) 2000-10-06
NO325824B1 NO325824B1 (no) 2008-07-21

Family

ID=22160544

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005043A NO325824B1 (no) 1998-04-07 2000-10-06 Efavirenz-kapsler eller -tabletter som omfatter et desintegreringsmiddel og en fremgangsmate for fremstilling av disse.

Country Status (27)

Country Link
US (2) US6238695B1 (no)
EP (1) EP1067936B1 (no)
JP (1) JP2002510634A (no)
KR (1) KR100634253B1 (no)
CN (1) CN1146419C (no)
AR (1) AR019031A1 (no)
AT (1) ATE223719T1 (no)
AU (1) AU756422B2 (no)
BR (1) BR9908810A (no)
CA (1) CA2321523C (no)
CZ (1) CZ300850B6 (no)
DE (1) DE69902893T2 (no)
DK (1) DK1067936T3 (no)
EA (1) EA003217B1 (no)
EE (1) EE04391B1 (no)
ES (1) ES2181417T3 (no)
HU (1) HU228498B1 (no)
IL (1) IL138078A (no)
NO (1) NO325824B1 (no)
NZ (1) NZ507566A (no)
PL (1) PL194309B1 (no)
PT (1) PT1067936E (no)
SK (1) SK284655B6 (no)
TW (1) TW576741B (no)
UA (1) UA72207C2 (no)
WO (1) WO1999051239A1 (no)
ZA (1) ZA200004313B (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72207C2 (uk) * 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
EP1332757B1 (en) * 1998-05-27 2012-06-13 Merck Sharp & Dohme Corp. Efavirenz compressed tablet formulation
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
ATE349203T1 (de) * 1998-06-11 2007-01-15 Pharmacia & Upjohn Co Llc Delavirdin tablettenformulierung
US7291352B2 (en) 2001-10-03 2007-11-06 Herbalscience Llc Methods and compositions for oral delivery of Areca and mate' or theobromine
US20050069596A1 (en) * 2001-10-03 2005-03-31 Gow Robert T. Compositions and methods comprising kava and anti-anxiety compounds
US7037524B2 (en) * 2001-10-03 2006-05-02 Herbalscience, Llc Oral delivery of a botanical
US20050053678A1 (en) * 2001-10-03 2005-03-10 Gow Robert T. Methods and compositions for betel nut chewing gum
AU2002359518A1 (en) * 2001-11-27 2003-06-10 Bristol-Myers Squibb Company Efavirenz tablet formulation having unique biopharmaceutical characteristics
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US20050037025A1 (en) * 2002-10-03 2005-02-17 Gow Robert T. Methods and compositions comprising kava and mate' or theobromine
PT1583542E (pt) 2003-01-14 2008-09-17 Gilead Sciences Inc Composições e métodos para terapia de combinação antiviral
US8021682B2 (en) * 2004-08-13 2011-09-20 Gallipot, Inc. Palatable suspending vehicle for pharmaceutical ingredients
US20060099253A1 (en) * 2004-10-20 2006-05-11 Wyeth Antibiotic product formulation
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
EP1912730A2 (en) * 2005-07-28 2008-04-23 Isp Investments Inc. Method to improve characteristics of spray dried powders and granulated materials, and the products thereby produced
US20070059360A1 (en) * 2005-07-29 2007-03-15 Ashish Jaiswal Water-dispersible anti-retroviral pharmaceutical compositions
ATE474560T1 (de) * 2005-12-14 2010-08-15 Cipla Ltd Pharmazeutische kombination aus nucleotid und nucleosid-reverse-transkriptase-hemmern (wie tenofovir und lamivudin) in verschiedenen teilen der dosiereinheit
EP2043613A1 (en) * 2006-07-14 2009-04-08 Fmc Corporation Solid form
MX2009002873A (es) * 2006-09-14 2009-05-19 Chemlink Lab Llc Metodo para preparar formas de dosis solida que forman una pasta, crema o gel cuando se diluyen para uso final.
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
WO2008080037A2 (en) * 2006-12-21 2008-07-03 Isp Investments Inc. Carotenoids of enhanced bioavailability
JP5508859B2 (ja) * 2007-01-26 2014-06-04 アイエスピー インヴェストメンツ インコーポレイテッド 噴霧乾燥製品を製造するための調剤処理方法
US20080181961A1 (en) * 2007-01-26 2008-07-31 Isp Investments, Inc. Amorphous oxcarbazepine and the production thereof
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
CA2697150A1 (en) * 2007-08-17 2009-02-26 Teva Pharmaceutical Industries Ltd. Methods and compositions for controlling the bioavailability of poorly soluble drugs
WO2010008719A2 (en) * 2008-06-16 2010-01-21 Schering Corporation Oral pharmaceutical formulations of vla-4 antagonists
WO2010125572A1 (en) * 2009-04-29 2010-11-04 Hetero Research Foundation Compressed tablets and capsules containing efavirenz
EP3351249A1 (en) 2010-01-27 2018-07-25 VIIV Healthcare Company Antiviral therapy
BR112012026843A2 (pt) * 2010-04-20 2016-07-12 Cipla Ltd composição, composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição e método para tratamento de hiv
CN114010776A (zh) 2010-06-09 2022-02-08 疫苗技术股份有限公司 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
CN102872019A (zh) * 2012-09-17 2013-01-16 北京阜康仁生物制药科技有限公司 一种采用微粉化技术的依非韦伦制剂
IN2013MU03370A (no) 2013-10-25 2015-09-25 Cipla Ltd
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
EP3334419A1 (en) 2015-08-14 2018-06-20 Sandoz AG Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
CN114404377B (zh) * 2022-01-10 2023-07-25 安徽贝克生物制药有限公司 一种阿巴卡韦、拉米夫定、依非韦伦复方片及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7084587A (en) 1986-04-01 1987-10-20 Upjohn Company, The Methylprednisolone/sodium carboxymethyl starch tablet composition
HU205717B (en) * 1989-04-28 1992-06-29 Daiichi Seiyaku Co Process for producing pharmaceutical composition against human immunodeficiency, comprising pyridionecarboxylic acid derivative
DK0577913T3 (da) * 1992-07-08 1998-01-26 Santen Oy Ophthalmisk præparat indeholdende timolol-hemihydrat
US5663169A (en) 1992-08-07 1997-09-02 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
WO1995020389A1 (en) * 1994-01-28 1995-08-03 Merck & Co., Inc. Benzoxazinones as inhibitors of hiv reverse transcriptase
US5663467A (en) * 1995-01-23 1997-09-02 Merck & Co., Inc. Synthesis of cyclopropylacetylene
IT1281502B1 (it) * 1995-06-13 1998-02-18 Sardinian Antiviral Research C Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della
UA72207C2 (uk) * 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
PE20000559A1 (es) 1998-05-27 2000-07-05 Merck & Co Inc Formulacion de tabletas comprimidas de efavirenz

Also Published As

Publication number Publication date
EA200001030A1 (ru) 2001-04-23
HU228498B1 (en) 2013-03-28
KR100634253B1 (ko) 2006-10-16
NO20005043L (no) 2000-10-06
US20010012518A1 (en) 2001-08-09
DK1067936T3 (da) 2003-02-17
CA2321523C (en) 2008-10-07
US6238695B1 (en) 2001-05-29
DE69902893T2 (de) 2003-04-30
US6555133B2 (en) 2003-04-29
CN1296412A (zh) 2001-05-23
SK14612000A3 (sk) 2001-07-10
CA2321523A1 (en) 1999-10-14
JP2002510634A (ja) 2002-04-09
EE04391B1 (et) 2004-12-15
ZA200004313B (en) 2002-01-30
CN1146419C (zh) 2004-04-21
NO325824B1 (no) 2008-07-21
AU756422B2 (en) 2003-01-09
TW576741B (en) 2004-02-21
EP1067936A1 (en) 2001-01-17
WO1999051239A1 (en) 1999-10-14
SK284655B6 (sk) 2005-08-04
HUP0101517A3 (en) 2002-11-28
EP1067936B1 (en) 2002-09-11
ATE223719T1 (de) 2002-09-15
CZ300850B6 (cs) 2009-08-26
EE200000589A (et) 2002-04-15
PT1067936E (pt) 2002-12-31
HUP0101517A2 (hu) 2001-11-28
PL194309B1 (pl) 2007-05-31
BR9908810A (pt) 2000-12-19
ES2181417T3 (es) 2003-02-16
KR20010042473A (ko) 2001-05-25
UA72207C2 (uk) 2005-02-15
AR019031A1 (es) 2001-12-26
PL343421A1 (en) 2001-08-13
EA003217B1 (ru) 2003-02-27
NZ507566A (en) 2002-11-26
IL138078A0 (en) 2001-10-31
AU3463799A (en) 1999-10-25
IL138078A (en) 2005-12-18
CZ20003571A3 (cs) 2001-01-17
DE69902893D1 (de) 2002-10-17

Similar Documents

Publication Publication Date Title
NO20005043L (no) Formulering av hurtigoppløsende efavirenz-kapsler eller - tabletter som benytter super-desintegreringsmidler
NO20003150D0 (no) FremgangsmÕte for fremstilling av tabletter som oppløses ved tygging
DK0966454T3 (da) Disubstituerede bicykliske heterocykler, deres fremstilling og deres anvendelse som lægemidler
NO20012915D0 (no) Ny farmasöytisk formulering
DK1073417T3 (da) Farmaceutisk aerosolformulering
FIU20000164U0 (fi) Uusi farmaseuttinen formulaatio
IS5541A (is) Áfangatöflur til inntöku
NO20020976D0 (no) Retarderte, orale, farmasöytiske administreringsformer
AR027162A1 (es) Compuestos de 2-fenil-3-fenoxilo-feniltio-benzotiofeno, sales farmaceuticamente aceptables de los mismos y composiciones farmaceuticas que los contienen
NO20040145L (no) Anvendelse av benzensulfonamidderivater for fremstilling av et medikament
NO20041998D0 (no) Benzoksazin og benzotiazinderivater og farmasoytiske sammensetninger som inneholder dem
NO996372L (no) Fast farmasøytisk preparat inneholdende benzofuanderivater
ITRM20000491A0 (it) Formulazione farmaceutica di propionato di fluticasone.
ID30032A (id) Formulasi farmasi
NO20002439D0 (no) Nye orale doseringsformer for carvediol
NO20021124L (no) Fremgangsmåte for fremstilling av benzoksazinderivater og mellomprodukter derfor
DK0994697T3 (da) Rapamycinformuleringer til oral indgivelse
AR025867A1 (es) Formulacion portasdora farmaceutica
DK0915087T3 (da) Sulfonamid-substituerede anellerede 5-leddede ringforbindelser, deres anvendelse som lægemiddel samt farmaceutiske præparater, som indeholder dem
NO20011402D0 (no) Tricykliske <delta>3-piperidiner som farmasøytiske midler
NO20002114L (no) Bisykliske forbindelser, fremgangsmÕte for deres fremstilling og farmasøytiske sammensetninger inneholdende dem
NO20004816D0 (no) Ny farmasøytisk formulering
NO20003393D0 (no) FremgangsmÕte for fremstilling av en farmasøytisk formulering
SI1067936T1 (en) Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
NO20030474D0 (no) Demens-legemiddel som inneholder 2-aryl-8- oksodihydropurinderivater som denaktive bestanddel

Legal Events

Date Code Title Description
MK1K Patent expired